

Galliprant
(grapiprant tablets)

**COMING
SOON
TO YOUR
PATIENTS IN
EARLY 2021**



Get ready for a revolution
in the treatment of
canine osteoarthritis!

Recommend Galliprant as first-line treatment

- **FIRST-IN-CLASS** non-COX inhibiting NSAID¹
- **UNIQUE MODE OF ACTION** specifically blocks the EP4 receptor, a key mediator of OA pain¹
- **FOR ALL STAGES** of OA from the earliest clinical signs



Simple, once-daily chewable tablet

For more information contact Elanco Ph: 1800 995 709 or email: ANZCustomerAdviceLine@elanco.com

INDICATION

Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.

IMPORTANT SAFETY INFORMATION

Read product leaflet for full instructions. The safety of Galliprant has not been established in dogs less than 3.6 kg or less than 9 months of age. The safe use of Galliprant has not been evaluated in dogs with cardiac disease, or dogs that are pregnant, lactating, or used for breeding. Concomitant use of Galliprant with other anti-inflammatory drugs should be avoided. Patients with gastrointestinal disease should be closely monitored during treatment. It is not known whether dogs with a history of hypersensitivity to sulfonamide drugs will exhibit hypersensitivity to Galliprant. Grapiprant is a methylbenzenesulfonamide. The following mild and generally transient adverse reactions have been observed in dogs treated with grapiprant: vomiting, diarrhoea, inappetence and lethargy.

1. Kirkby Shaw, K, et al. Vet Med Sci. 2016;2:3-9.